COLO B Coloplast A/S Class B

Coloplast A/S - Announcement no. 08/2022 - Financial Calendar 2022-23

Coloplast A/S - Announcement no. 08/2022 - Financial Calendar 2022-23



 

Please see enclosed pdf.

For more information and calendar invitations for upcoming events, please visit: 

Kind regards,

Investor Relations

Coloplast A/S

Tel.

 

For further information, please contact

  

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Aleksandra Dimovska

Director, Investor Relations

Tel. /

Email:

Kristine Husted Munk

Sr. Manager, Investor Relations

Tel. /

Email:                                                                        

Press and the media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR) no. 69749917

Website



 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound & Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ about 14,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2022-09.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.



 

Attachment



EN
08/09/2022

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Free Trial
COLO B Coloplast A/S C...

Coloplast AS: 1 director

A director at Coloplast AS bought 2,150 shares at 463.200DKK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

COLO B COLOPLAST A/S CLASS B
5h / 1m 5h / 1m 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

19h / 55m 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

19h / 55m 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast udnævner Gavin Wood som ny CEO

Coloplast udnævner Gavin Wood som ny CEO Selskabsmeddelelse nr. 3/2026 Intern viden Coloplast udnævner Gavin Wood som ny CEO Det er med glæde, at Coloplasts bestyrelse kan annoncere udnævnelsen af Gavin Wood som ny CEO fra den 1. maj 2026. Gavin Wood afløser Lars Rasmussen, der har været midlertidig CEO siden den 5. maj 2025. Gavin Wood har i to årtier bestredet forskellige ledelsesroller i Johnson & Johnson, senest som øverste leder for Johnson & Johnson MedTech EMEA, en forretning der omsætter for adskillige milliarder dollars og har mere end 7000 medarbejdere på tværs af tre forretnin...

March 4, 2026 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast appoints Gavin Wood as new CEO

Coloplast appoints Gavin Wood as new CEO Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-do...

March 4, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch